Pinealon Dosage Guide

Evidence-based protocols for the Khavinson brain bioregulator peptide — neuroprotection, melatonin regulation, cognitive support, cycling, stacking with Epitalon, and safety.

Last reviewed February 24, 2026

What Is Pinealon?

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the Khavinson bioregulator peptide family — a class of ultra-short synthetic peptides (2–4 amino acids) designed to regulate tissue-specific gene expression. Pinealon is the brain- and pineal gland-specific bioregulator in this family.

Unlike conventional Western peptides that typically work through receptor binding and acute pharmacological effects, Khavinson bioregulators operate on a fundamentally different paradigm. The theory proposes that these short peptides interact directly with DNA regulatory regions in target cells, modulating gene expression in a tissue-specific manner. For Pinealon, the target tissues are neurons and pinealocytes (the melatonin-producing cells of the pineal gland).

Pinealon's proposed mechanisms include regulation of melatonin synthesis in pinealocytes, neuroprotective effects against oxidative stress and excitotoxicity, normalization of circadian rhythms via pineal function restoration, and enhancement of cognitive function. It is often compared to Epitalon — another Khavinson peptide targeting the pineal gland — but the two serve distinct purposes. Epitalon (Ala-Glu-Asp-Gly) primarily activates telomerase for anti-aging via telomere maintenance, while Pinealon (Glu-Asp-Arg) focuses on neuroprotection and melatonin regulation. They are complementary, not redundant.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from published Khavinson protocols and community experience and community protocols — not from approved pharmaceutical labeling.

Key Characteristics:

  • Khavinson bioregulatorpart of the short peptide bioregulator family developed at the St. Petersburg Institute of Bioregulation and Gerontology
  • Tripeptide3 amino acids: Glu-Asp-Arg (glutamic acid–aspartic acid–arginine)
  • Brain & pineal gland specifictargets neurons and pinealocytes for neuroprotection and melatonin synthesis regulation
  • Gene expression modulationproposed mechanism involves direct peptide-DNA interaction at regulatory regions in target cells, not conventional receptor binding
  • Short intensive cycles10–20 day cycles repeated every 3–6 months — standard Khavinson bioregulator protocol
  • Short plasma half-liferapid clearance (minutes), but bioregulatory effects on gene expression are theorized to persist well beyond administration

For a complete overview of its mechanism and research, see our full Pinealon profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Pinealon Dosage Is Determined

Pinealon dosing follows the Khavinson bioregulator paradigm, which differs fundamentally from conventional Western peptide pharmacology. Rather than dose-response curves based on receptor saturation kinetics, Khavinson bioregulators use standardized short-cycle protocols established through decades of research at the St. Petersburg Institute. The dosing framework is based on published Russian research, preclinical studies, and clinical observations.

The Khavinson Bioregulator Framework

Khavinson's bioregulation theory proposes that short peptides (2–4 amino acids) can be synthesized to match the regulatory peptides naturally produced during protein metabolism in specific tissues. When administered exogenously, these peptides are theorized to interact with complementary DNA sequences in target cells, restoring optimal gene expression patterns that may decline with aging or disease. The standard protocol uses intensive short cycles (10–20 days) rather than continuous administration, because the gene expression changes are proposed to persist long after peptide clearance.

Preclinical Neuroprotection Studies

Research from Khavinson's group has demonstrated Pinealon's neuroprotective effects in cell culture models. Studies published in the Bulletin of Experimental Biology and Medicine showed that Pinealon protected cortical neurons against oxidative stress-induced apoptosis and reduced markers of excitotoxicity. These studies used concentrations in the nanomolar-to-micromolar range, supporting the low-dose protocol used clinically.

Gene Expression Studies

Published work from the St. Petersburg Institute has demonstrated that Pinealon modulates expression of genes involved in neuroprotection, antioxidant defense, and melatonin synthesis in pinealocyte cultures. Khavinson et al. reported that short peptides, including Pinealon, can penetrate cell membranes and interact with DNA in the nucleus, affecting transcription of target genes. These findings, while published in peer-reviewed journals, await independent replication by Western laboratories.

Clinical Use in Russia

In Russia, Pinealon has been used clinically as a dietary supplement for age-related cognitive decline, sleep disorders, and neuroprotection. The oral capsule form (10 mg, 1–2x daily for 10–30 days) has been available through Russian pharmacies. Clinical observations from Russian practitioners inform the dosing ranges used in the research peptide community, though formal Western clinical trials have not been conducted.

Strength of evidence: Moderate-to-limited. Pinealon has published peer-reviewed research demonstrating neuroprotective effects in cell culture and animal models, plus decades of clinical use in Russia. However, large-scale randomized controlled trials are absent, and most published work originates from Khavinson's group. Independent Western replication is limited. Dosing protocols are based on the established Khavinson framework and community experience. Users should approach with informed awareness of these evidence limitations.

Standard Pinealon Dosage Ranges

Pinealon is available in multiple administration routes: subcutaneous injection (most common in the research peptide community), intranasal, and oral capsules (primarily in Russia). The standard Khavinson protocol uses short, intensive cycles of 10–20 days, repeated every 3–6 months.

Dosage by Administration Route

RouteDoseFrequencyCycle LengthNotes
Subcutaneous (standard)1–5 mg1x daily10–20 daysMost common research protocol; best bioavailability
Subcutaneous (extended range)5–10 mg1x daily10–20 daysHigher dose used by experienced users; limited additional data
Intranasal1–5 mg1x daily10–20 daysMay offer more direct CNS access; variable absorption
Oral capsule (Russia)10 mg1–2x daily10–30 daysHigher dose compensates for lower oral bioavailability

Dosage by Experience Level (Subcutaneous)

LevelDoseFrequencyCycleNotes
Beginner1–2 mg1x daily10 daysAssess tolerance; standard starting point for first cycle
Intermediate3–5 mg1x daily10–20 daysStandard protocol for most users after initial cycle
Advanced5–10 mg1x daily15–20 daysUpper range; limited data above 10 mg supporting additional benefit

Injection Timing

  • Morning or evening: Either timing is acceptable. Some users prefer evening administration due to Pinealon's potential effects on melatonin regulation and sleep quality
  • Consistency matters: Choose a consistent time each day throughout the 10–20 day cycle
  • Fasting not required: Unlike GH-releasing peptides, Pinealon does not require fasted injection. However, empty stomach may improve absorption
  • Once daily is sufficient: The bioregulator paradigm uses single daily dosing — multiple daily injections are not part of the standard protocol

Verified sources for Pinealon

These vendors are vetted by PeptideWiki for purity testing and COA transparency.

SwissChems10% off
View all vendor deals·Affiliate links. Commission at no extra cost.

Khavinson Bioregulator Comparison

Pinealon belongs to a family of Khavinson bioregulator peptides, each targeting specific tissues. Understanding how Pinealon compares to related bioregulators helps clarify its unique role and identify complementary protocols. This table compares the most commonly used Khavinson bioregulators.

ParameterPinealonEpitalonCortagenVilon
SequenceGlu-Asp-ArgAla-Glu-Asp-GlyAla-Glu-Asp-ProLys-Glu
LengthTripeptide (3 AA)Tetrapeptide (4 AA)Tetrapeptide (4 AA)Dipeptide (2 AA)
Target TissueBrain / Pineal glandPineal glandBrain / Cerebral cortexThymus / Immune system
Primary MechanismNeuroprotection + melatonin regulationTelomerase activationCerebral cortex bioregulationImmune function restoration
Primary UseCognitive support, sleep, neuroprotectionAnti-aging, telomere maintenanceBrain function, neurodegenerative conditionsImmune support, anti-aging
Standard Cycle10–20 days10–20 days10–20 days10–20 days
Rest Period3–6 months3–6 months3–6 months3–6 months
Complementary ToEpitalon, Cortagen, SemaxPinealon, VilonPinealon, EpitalonEpitalon, Thymalin
Key distinction: Pinealon and Epitalon both target the pineal gland but through different mechanisms. Epitalon activates telomerase for telomere maintenance (anti-aging). Pinealon modulates neuroprotective gene expression and melatonin synthesis (brain health). They are commonly stacked together for comprehensive pineal and brain support. Cortagen is the complementary brain cortex bioregulator, targeting different neural populations than Pinealon.

Calculate Your Pinealon Dose

Pinealon is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

  • Vial size: 10 mg (10,000 mcg) of Pinealon
  • Bacteriostatic water added: 2 mL
  • Concentration: 10,000 mcg ÷ 2 mL = 5,000 mcg per mL (5 mg/mL)
  • Target dose: 3 mg (3,000 mcg)
  • Volume to draw: 3,000 ÷ 5,000 = 0.6 mL = 60 units on an insulin syringe

Quick Reference — 10 mg Vial

Bac Water AddedConcentration1 mg Dose3 mg Dose5 mg Dose
1 mL10 mg/mL10 units (0.1 mL)30 units (0.3 mL)50 units (0.5 mL)
2 mL5 mg/mL20 units (0.2 mL)60 units (0.6 mL)100 units (1.0 mL)
2.5 mL4 mg/mL25 units (0.25 mL)75 units (0.75 mL)125 units (1.25 mL)

Quick Reference — 5 mg Vial

Bac Water AddedConcentration1 mg Dose3 mg Dose5 mg Dose
1 mL5 mg/mL20 units (0.2 mL)60 units (0.6 mL)100 units (1.0 mL)
2 mL2.5 mg/mL40 units (0.4 mL)120 units (1.2 mL)200 units (2.0 mL)

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

Pinealon Dosage by Goal

Pinealon's primary applications center on neuroprotection, cognitive support, sleep quality, and brain anti-aging. The optimal protocol varies depending on whether you are targeting sleep and circadian rhythm restoration, cognitive enhancement, neuroprotection, or comprehensive brain anti-aging.

Sleep Quality & Circadian Rhythm Restoration

For users seeking to normalize melatonin production and improve sleep quality through restoration of pineal gland function. This is one of the most common applications, particularly for individuals with age-related melatonin decline or disrupted circadian rhythms. Effects on sleep quality are often the first noticeable benefit, typically within 5–10 days.

  • Dose: 1–3 mg SubQ daily
  • Timing: Evening administration (2–3 hours before bed)
  • Cycle: 10–20 days, repeat every 3–6 months
  • Note: Pinealon aims to restore the pineal gland's own melatonin production — it is not exogenous melatonin. Effects may be gradual and persist beyond the cycle

Cognitive Enhancement & Neuroprotection

For users targeting improvements in memory, attention, and neuronal health. This protocol uses the mid-range dose and full cycle duration for maximum neuroprotective benefit. Cognitive effects are typically more subtle than sleep improvements and may develop over weeks to months, including during the rest period.

  • Dose: 3–5 mg SubQ daily
  • Timing: Morning or evening (consistent timing preferred)
  • Cycle: 15–20 days, repeat every 4–6 months
  • Stack: Consider adding Semax for complementary nootropic effects through BDNF upregulation

Age-Related Cognitive Decline

For older adults concerned about age-related cognitive decline and brain aging. This is the most studied application in Khavinson's published work. The protocol uses standard dosing with more frequent cycling (every 3–4 months rather than 6) for sustained bioregulatory effects. Combining with Cortagen (brain cortex bioregulator) and Epitalon provides the most comprehensive brain anti-aging approach within the Khavinson framework.

  • Dose: 3–5 mg SubQ daily
  • Timing: Morning or evening
  • Cycle: 10–20 days, repeat every 3–4 months
  • Stack: + Epitalon (pineal anti-aging) + Cortagen (brain cortex bioregulation) for comprehensive brain support
Important context: While Khavinson's group has published research on bioregulator peptides in elderly populations showing improvements in cognitive function and mortality, these studies have limitations including small sample sizes and lack of independent replication. The protocol is based on the best available evidence from this research tradition, but users should maintain realistic expectations.

Comprehensive Brain Anti-Aging

The most thorough approach within the Khavinson bioregulator paradigm, combining Pinealon with complementary bioregulators for multi-target brain and pineal support. This protocol is used by experienced bioregulator users seeking the full spectrum of proposed neuroprotective and geroprotective effects.

  • Dose: 5–10 mg SubQ daily
  • Timing: Consistent daily timing throughout cycle
  • Cycle: 15–20 days, repeat every 3–6 months
  • Full stack: Pinealon + Epitalon + Cortagen (run simultaneously during cycle)
The bioregulator approach is cumulative. Khavinson's framework proposes that benefits accumulate across repeated cycles over months and years. Single cycles may produce modest effects; the protocol is designed for long-term, repeated application. Patience and consistency across multiple cycles is the intended approach.

Cycling Protocols

Cycling is the defining feature of Khavinson bioregulator protocols. Unlike conventional peptides that may be used continuously, bioregulators use short, intensive cycles separated by extended rest periods. This is not a desensitization concern (as with GHRPs) but rather the intended protocol design — the theory proposes that gene expression changes initiated during the cycle persist and develop during the rest period.

Standard Cycling Protocols

ProtocolCycle DurationRest PeriodCycles per YearNotes
Conservative10 days6 months2Minimum effective protocol; ideal for first-time users
Standard10–20 days4–6 months2–3Most common protocol; balances cycle duration with rest
Intensive20 days3–4 months3–4More frequent cycling for age-related concerns; maximum protocol

Annual Cycling Strategy

A common approach is to run 2–3 Pinealon cycles per year, spaced evenly. For example: a 20-day cycle in January, a 20-day cycle in May, and a 20-day cycle in September. This provides regular bioregulatory input while maintaining adequate rest periods for the proposed gene expression effects to develop.

Combining Cycles with Other Bioregulators

When stacking Pinealon with other Khavinson bioregulators (such as Epitalon or Cortagen), all bioregulators in the stack are typically run simultaneously during the same cycle window. You do not need to stagger them — they target different aspects of the same tissues and are designed to be used concurrently. This simplifies scheduling and reduces the total number of injection days per year.

What to expect during rest periods: Do not interpret the rest period as “losing gains.” The Khavinson framework proposes that bioregulatory effects continue to develop during the rest period as gene expression changes initiated by the peptide work through cellular processes. Some users report progressive improvements in sleep quality and cognition weeks after completing a cycle.

Pinealon Stacking Protocols

Pinealon stacking follows the Khavinson bioregulator philosophy of complementary tissue-specific peptides working in concert. The most effective stacks combine Pinealon with other bioregulators targeting the pineal gland (Epitalon) or brain (Cortagen), or with Western nootropic peptides (Semax, Selank) for complementary cognitive and neuroprotective effects.

Pinealon + Epitalon — Comprehensive Pineal Support

The most popular Pinealon stack. Pinealon provides neuroprotection and melatonin synthesis regulation, while Epitalon activates telomerase in pineal tissue for anti-aging. Both target the pineal gland through different mechanisms, making them highly complementary. This is the standard Khavinson pineal gland protocol.

CompoundDoseFrequencyPurpose
Pinealon3–5 mg SubQ1x daily for 10–20 daysNeuroprotection + melatonin synthesis regulation
Epitalon5–10 mg SubQ1x daily for 10–20 daysTelomerase activation + pineal gland anti-aging
Protocol note: Run Pinealon and Epitalon simultaneously during the same cycle window. They can be injected at the same time of day (separate injection sites) or at different times. Both follow the same 10–20 day cycle with 3–6 month rest periods. This is the most straightforward Khavinson bioregulator stack.

Pinealon + Cortagen (Dual Brain Bioregulator)

Combines two brain-targeting bioregulators for comprehensive central nervous system support. Pinealon targets the pineal gland and neuroprotection, while Cortagen (Ala-Glu-Asp-Pro) is the cerebral cortex bioregulator, targeting higher cognitive functions. Together they provide multi-region brain bioregulation.

CompoundDoseFrequencyPurpose
Pinealon3–5 mg SubQ1x daily for 10–20 daysPineal gland bioregulation + neuroprotection
Cortagen1–3 mg SubQ1x daily for 10–20 daysCerebral cortex bioregulation + cognitive function

Pinealon + Semax (Bioregulator + Nootropic)

Bridges the Khavinson bioregulator and Western nootropic peptide paradigms. Semax is a synthetic heptapeptide analog of ACTH(4-10) that upregulates BDNF (brain-derived neurotrophic factor) and provides acute cognitive enhancement. Paired with Pinealon's longer-term neuroprotective gene expression effects, this stack provides both immediate nootropic benefit and sustained bioregulatory support.

CompoundDoseFrequencyPurpose
Pinealon3–5 mg SubQ1x daily for 10–20 daysLong-term neuroprotection + melatonin regulation
Semax200–600 mcg intranasal1–2x daily (ongoing or cycled)BDNF upregulation, acute cognitive enhancement

Pinealon + Selank (Neuroprotection + Anxiolysis)

For users seeking neuroprotection combined with anxiety reduction and stress resilience. Selank is a synthetic heptapeptide with anxiolytic and nootropic properties, modulating GABA, serotonin, and dopamine systems. Combined with Pinealon's melatonin regulation and neuroprotective effects, this stack supports both daytime cognitive resilience and nighttime sleep quality.

CompoundDoseFrequencyPurpose
Pinealon3–5 mg SubQ1x daily for 10–20 daysNeuroprotection + melatonin/sleep regulation
Selank250–500 mcg intranasal1–3x daily (ongoing or cycled)Anxiolysis, stress resilience, GABAergic modulation

Full Khavinson Brain Protocol (Pinealon + Epitalon + Cortagen)

The comprehensive brain and pineal anti-aging stack using three complementary Khavinson bioregulators. This protocol targets pineal melatonin function (Pinealon), telomere maintenance (Epitalon), and cerebral cortex bioregulation (Cortagen) simultaneously. Used by experienced bioregulator users for maximum neuroprotective coverage.

CompoundDoseFrequencyPurpose
Pinealon3–5 mg SubQ1x daily for 10–20 daysPineal neuroprotection + melatonin regulation
Epitalon5–10 mg SubQ1x daily for 10–20 daysTelomerase activation + pineal anti-aging
Cortagen1–3 mg SubQ1x daily for 10–20 daysCerebral cortex bioregulation

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Reported Side Effects

Rare and generally mild:

  • Drowsiness — the most commonly reported effect, likely related to melatonin modulation. Usually mild and may actually be beneficial for users targeting sleep improvement
  • Injection site reactions — mild redness, minor soreness at the injection site. Typical of subcutaneous peptide injection and generally resolves quickly
  • Headache — rare, usually mild and transient. More commonly reported in the first few days of a cycle
  • Vivid dreams — some users report more vivid or memorable dreams during Pinealon cycles, potentially related to melatonin and sleep architecture effects

Not reported in published literature:

  • Hormonal disruption (cortisol, prolactin, testosterone, estrogen)
  • Organ toxicity
  • Dependency or withdrawal effects
  • Significant GI disturbance (with SubQ administration)
The extremely mild side effect profile is consistent with the Khavinson bioregulator class generally. These ultra-short peptides (2–4 amino acids) at low doses during brief cycles represent a very different risk profile compared to larger, more pharmacologically active peptides. However, absence of reported adverse effects should be interpreted cautiously given the limited scope of published safety data.

Contraindications

  • Active cancer or history of cancer — any compound that modulates gene expression should be avoided in the presence of active malignancy. While Pinealon has not been shown to promote tumor growth, the theoretical concern is sufficient to warrant avoidance.
  • Pregnancy and breastfeeding — no safety data exists for Pinealon during pregnancy or nursing. Any peptide that modulates gene expression should be avoided during these periods as a precautionary measure.
  • Autoimmune neurological conditions — conditions such as multiple sclerosis or autoimmune encephalitis represent situations where immune-modulated CNS activity could theoretically be affected by bioregulator peptides. Use only under medical supervision.
  • Known allergy to component amino acids — while extremely rare, hypersensitivity to any of the three amino acids (glutamic acid, aspartic acid, arginine) is a contraindication.
  • Concurrent melatonin supplementation at high doses — if Pinealon increases endogenous melatonin production as theorized, combining with high-dose exogenous melatonin could lead to excessive melatonin levels. Coordinate with a healthcare provider if using both.

When to Stop or Reduce Dose

  • Excessive drowsiness that impairs daytime function — reduce dose or switch to evening-only administration
  • Persistent headache beyond the first 3–4 days of the cycle
  • Any allergic reaction (rash, swelling, difficulty breathing) — discontinue immediately and seek medical attention
  • Any symptom that feels unusual or concerning — err on the side of caution and discontinue
Regulatory Status: Pinealon is not FDA-approved for any medical use. In Russia, it is available as a dietary supplement (not a prescription drug). In Western countries (US, EU, UK), it is classified as a research peptide. It is not available through conventional pharmacies. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common Pinealon Dosing Mistakes

Avoid these common errors to get the most out of your Pinealon protocol:

Frequently Asked Questions

Key Takeaways

  • Pinealon (Glu-Asp-Arg) is a Khavinson bioregulator peptide — it targets the brain and pineal gland specifically, modulating gene expression in neurons and pinealocytes
  • Standard dose: 1–5 mg SubQ, once daily for 10–20 days — followed by a 3–6 month rest period (standard Khavinson protocol)
  • Different paradigm from Western peptides — Khavinson bioregulators use short intensive cycles, not continuous daily dosing. The rest period is part of the protocol
  • Primary applications: neuroprotection, melatonin synthesis regulation, cognitive support, circadian rhythm normalization, brain anti-aging
  • Distinct from Epitalon: both target the pineal gland but through different mechanisms. Epitalon activates telomerase; Pinealon focuses on neuroprotection and melatonin. They are complementary, not redundant
  • Best stacks: Epitalon (pineal synergy), Cortagen (brain bioregulator synergy), Semax (nootropic), Selank (anxiolysis)
  • Extremely mild side effect profile — drowsiness, rare injection site reactions, and infrequent headache are the only commonly reported effects
  • Evidence base is moderate-to-limited — most research from Khavinson's group with limited independent Western replication. Peer-reviewed publications exist but large-scale clinical trials are absent
  • Available in multiple forms: SubQ injection (most common), intranasal, oral capsules (Russia). SubQ provides the best bioavailability
  • Not FDA-approved — classified as a research peptide in Western countries. Available as a dietary supplement in Russia. Check local regulations.

This article is for educational and informational purposes only. See our Disclaimer.

References

  1. Khavinson VKh, et al. “Peptide regulation of gene expression and protein synthesis in bronchial epithelium.” Lung. 2014;192(6):781-791. PubMed
  2. Khavinson VKh, et al. “Short peptides modulate the effect of endonucleases of wheat germ on DNA.” Bull Exp Biol Med. 2010;149(1):110-113.
  3. Khavinson VKh, Malinin VV. “Gerontological aspects of genome peptide regulation.” Basel: Karger. 2005.
  4. Khavinson VKh. “Peptides and Ageing.” Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PubMed
  5. Kozina LS, et al. “Pinealon promotes cell viability by suppression of free radicals and pro-inflammatory cytokines.” Bull Exp Biol Med. 2008;145(4):467-470.
  6. Khavinson VKh, et al. “Neuroprotective effect of EDR peptide in models of Alzheimer's disease.” Bull Exp Biol Med. 2011;151(1):89-92.
  7. Fedoreyeva LI, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry (Mosc). 2011;76(11):1210-1219. PubMed
  8. Khavinson VKh, et al. “Effect of Livagen peptide on chromatin activation in lymphocytes from old individuals.” Bull Exp Biol Med. 2002;134(4):389-392. PubMed
  9. Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139-149. PubMed
  10. Khavinson VKh, et al. “Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression.” Biol Bull Rev. 2013;3(6):451-455.

Download This Guide as a PDF

Take the complete Pinealon Dosage Guide with you. All sections, dosing tables, and FAQ — formatted for easy reference.

Free. No spam. Unsubscribe anytime.